Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $116.00 at Robert W. Baird

Axsome Therapeutics (NASDAQ:AXSM) had its target price upped by Robert W. Baird from $112.00 to $116.00 in a research note released on Wednesday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Several other analysts have also recently commented on AXSM. UBS Group reduced their price objective on shares of Axsome Therapeutics from $107.00 to $105.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 price target on shares of Axsome Therapeutics in a research note on Monday, September 16th. Wells Fargo & Company began coverage on Axsome Therapeutics in a report on Tuesday, September 3rd. They set an “overweight” rating and a $140.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $180.00 price target on shares of Axsome Therapeutics in a research report on Thursday, September 5th. Finally, Royal Bank of Canada boosted their price objective on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. One analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $124.93.

Axsome Therapeutics Trading Up 2.2 %

NASDAQ AXSM opened at $99.94 on Wednesday. Axsome Therapeutics has a one year low of $56.66 and a one year high of $105.00. The firm has a market cap of $4.75 billion, a PE ratio of -14.98 and a beta of 1.26. The firm’s fifty day moving average is $90.59 and its two-hundred day moving average is $84.05. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.40 and a current ratio of 2.44.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The company had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. During the same quarter in the previous year, the company earned ($1.32) EPS. Analysts expect that Axsome Therapeutics will post -5.12 earnings per share for the current year.

Insider Transactions at Axsome Therapeutics

In other news, Director Mark E. Saad sold 11,016 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total value of $1,005,870.96. Following the completion of the sale, the director now directly owns 10,002 shares in the company, valued at approximately $913,282.62. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 22.40% of the company’s stock.

Institutional Trading of Axsome Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in AXSM. Northwestern Mutual Wealth Management Co. bought a new stake in Axsome Therapeutics in the 2nd quarter valued at about $27,000. EntryPoint Capital LLC bought a new position in Axsome Therapeutics in the 1st quarter worth approximately $35,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Axsome Therapeutics during the 2nd quarter valued at $47,000. Russell Investments Group Ltd. raised its stake in Axsome Therapeutics by 5,550.0% during the 1st quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock valued at $63,000 after acquiring an additional 777 shares in the last quarter. Finally, Covestor Ltd boosted its position in Axsome Therapeutics by 54,750.0% during the 1st quarter. Covestor Ltd now owns 1,097 shares of the company’s stock worth $88,000 after acquiring an additional 1,095 shares during the period. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.